These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 28829236)

  • 21. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
    Lomonte ABV; Radominski SC; Marcolino FMD; Brenol CV; Zerbini CAF; García EG; Akylbekova EL; Rojo R; de Leon DP
    Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
    Tanaka Y; Yamaoka K
    Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1102-1107. PubMed ID: 28356243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
    Clowse ME; Feldman SR; Isaacs JD; Kimball AB; Strand V; Warren RB; Xibillé D; Chen Y; Frazier D; Geier J; Proulx J; Marren A
    Drug Saf; 2016 Aug; 39(8):755-62. PubMed ID: 27282428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
    Qiu Q; Feng Q; Tan X; Guo M
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC; Song GG
    Rheumatol Int; 2015 Dec; 35(12):1965-74. PubMed ID: 25994093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
    Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib for the treatment of rheumatoid arthritis: an update.
    Yamaoka K
    Expert Rev Clin Immunol; 2019 Jun; 15(6):577-588. PubMed ID: 30998415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib in the treatment of active rheumatoid arthritis in adults.
    Fleischmann R
    Immunotherapy; 2018 Jan; 10(1):39-56. PubMed ID: 29043892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib: A Review in Rheumatoid Arthritis.
    Dhillon S
    Drugs; 2017 Dec; 77(18):1987-2001. PubMed ID: 29139090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
    Fleischmann R; Kremer J; Tanaka Y; Gruben D; Kanik K; Koncz T; Krishnaswami S; Wallenstein G; Wilkinson B; Zwillich SH; Keystone E
    Int J Rheum Dis; 2016 Dec; 19(12):1216-1225. PubMed ID: 27451980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
    Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Wiśniewska N; Pilc A
    Clin Rheumatol; 2013 Oct; 32(10):1415-24. PubMed ID: 23877486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
    Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
    Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
    Ann Intern Med; 2013 Aug; 159(4):I-26. PubMed ID: 24026272
    [No Abstract]   [Full Text] [Related]  

  • 40. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
    Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
    Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.